Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)

Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, Schönau V, Simon D, Kleinert S, Baraliakos X, Braun J, Hueber A, Fleck M, Rubbert-Roth A, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Glaser C, Filkova M, Feist E, Burmester G, Karberg K, Strunk J, Canete J, Senolt L, Naredo E, Schett G (2022)


Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 1067-1069

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Rech, J., Kleyer, A., Ostergaard, M., Hagen, M., Mendez, L.V., Tascilar, K.,... Schett, G. (2022). Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study). In ARTHRITIS & RHEUMATOLOGY (pp. 1067-1069). HOBOKEN: WILEY.

MLA:

Rech, Jürgen, et al. "Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2022. 1067-1069.

BibTeX: Download